• Stoke Therapeutics recently reported past first-quarter results and business updates, highlighting four years of Phase 1/2a data for zorevunersen showing sustained cognitive, behavioral, and seizure improvements, with patients treated for more than five years and the therapy remaining generally well tolerated.
• The company also outlined a path toward late-stage development, targeting completion of enrollment in the Phase 3 EMPEROR trial by June 2026 to support mid-2027 data and a rolling US NDA submission planned for the first quarter of 2027, potentially reinforcing confidence in its rare disease pipeline.
• We will now examine how the long-term zorevunersen data and Phase 3 timelines could influence Stoke Therapeutics' existing investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics, you need to believe that zorevunersen can convert encouraging early and open label Dravet data into a successful Phase 3 outcome and eventual regulatory approval. The latest four year dataset and clarified EMPEROR timeline appear to strengthen the case for this near term catalyst, while the main risk remains that the long, controlled Phase 3 trial fails to mirror the earlier seizure and cognitive benefits or runs into regulatory delays.

Among recent updates, the most relevant is Stoke’s expectation to complete EMPEROR enrollment by June 2026 and pursue a rolling US NDA starting in the first quarter of 2027. This timeline, paired with the multi year safety and efficacy profile just reported, tightens the focus on mid 2027 data as the key inflection point for the story and frames how investors might weigh clinical risk against the company’s ongoing losses and cash needs.

However, investors should also be aware that if EMPEROR results fall short or the FDA requires more data, the impact on approval timing and Stoke’s cash runway could...

Stoke Therapeutics' narrative projects $81.1 million revenue and $13.2 million earnings by 2028. This implies a 26.7% yearly revenue decline and an earnings decrease of $27.4 million from $40.6 million today.

Uncover how Stoke Therapeutics' forecasts yield a $34.25 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming revenue could fall about 50% annually and still require a very high PE multiple, which highlights how cautious views on EMPEROR outcomes and payer access can differ sharply from more optimistic takes, and why it is worth considering how the new long term data and updated timelines might shift those expectations.

Explore 4 other fair value estimates on Stoke Therapeutics - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.